Stachybotrys chartarum-Induced Hypersensitivity Pneumonitis Is TLR9 Dependent
نویسندگان
چکیده
منابع مشابه
TLR9-dependent IL-23/IL-17 is required for the generation of Stachybotrys chartarum-induced hypersensitivity pneumonitis.
Hypersensitivity pneumonitis (HP) is an inflammatory lung disease that develops after repeated exposure to inhaled particulate Ag. Stachybotrys chartarum is a dimorphic fungus that has been implicated in a number of respiratory illnesses, including HP. In this study, we have developed a murine model of S. chartarum-induced HP that reproduces pathology observed in human HP, and we have hypothesi...
متن کاملThe Pathogenicity of Stachybotrys chartarum.
Stachybotrys chartarum is a dematiaceous fungus that is ubiquitous in our living environment. This fungus has long been regarded as non-pathogenic and its inhalation effect on humans has been scarcely studied. Recently, however, epidemiologic studies on acute idiopathic pulmonary hemorrhage in infants suggested that the fungus might be potentially pathogenic to humans. To determine the pathogen...
متن کاملCryptic species in Stachybotrys chartarum.
Stachybotrys chartarum has received much attention as a possible cause of sick-building syndrome. Because morphological species recognition in fungi can hide diversity, we applied a phylogenetic approach to search for cryptic species. We examined 23 isolates from the San Francisco Bay Area, and another seven from around the US. Using markers we developed for three polymorphic protein coding loc...
متن کاملLenalidomide-induced hypersensitivity pneumonitis.
symptoms recovered within few days. The transbronchial biopsies in the patients described by Lerch et al. [1] and Thornburg et al. [2] revealed a nonspecific, hypersensitivity pneumonitis (compatible with toxic drug-induced damage). Immunosuppressive therapy with steroids induced a rapid relief of all symptoms in all 3 cases. Infectious cause of the pulmonary infiltrates could be excluded by br...
متن کاملRituximab-induced hypersensitivity pneumonitis.
Rituximab is a chimeric anti-CD20 monoclonal antibody used to treat CD20+ non-Hodgkin's lymphoma. Although pulmonary adverse reactions such as cough, rhinitis, bronchospasm, dyspnea and sinusitis are relatively common, other respiratory conditions like cryptogenic organizing pneumonia, interstitial pneumonitis and diffuse alveolar hemorrhage have rarely been reported. Only 2 possible cases of r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The American Journal of Pathology
سال: 2011
ISSN: 0002-9440
DOI: 10.1016/j.ajpath.2011.08.019